Biologics for the management of dementia

Chaurasiya, Akash; Katke, Sumeet; Panchal, Kanan; Nirmal, Jayabalan

doi:10.1016/b978-0-12-824331-2.00001-7

Cited by 1 publication

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there were discouraging results in a phase 3 study that was carried out on patients with prodromal AD because of a lack of efficiency of treatment compared with placebo, there were still a diminution of Aβ plaques. There results may suggest that despite a reduction in the amyloid levels at the minimum concentration of the drug, higher doses may be needed to achieve a clinically efficient response [20,21].…”

Section: Resultsmentioning

confidence: 99%

Monoclonal antibodies treatment for Alzheimer’s dementia – a literature review

Horosan¹,

Nistor²,

Zaharia³

2021

Ro J Psychiatry Psychother.

View full text Add to dashboard Cite

Alzheimer’s disease (AD), recognized by the World Health Organization (WHO) as one of the leading causes of death and disability among older people globally, is the most common form of dementia. The accumulation of amyloid plaques and neurofibrillary tangles in the brain leads to synaptic and neuronal loss, causing cognitive impairment and functional decline. Current treatment options, such as cholinesterase inhibitors and NMDA receptor antagonists, provide partial symptomatic relief but do not alter disease progression. Monoclonal antibodies targeting amyloid-β (Aβ) have emerged as potential disease-modifying therapies by promoting the clearance of Aβ plaques. This paper reviews recent scientific literature and ongoing clinical trials related to monoclonal antibody treatments for AD. Aducanumab, Bapineuzumab, Gantenerumab, Lecanemab, and Solanezumab are among the most discussed monoclonal antibodies. Aducanumab, which has received accelerated approval from the FDA, demonstrates efficacy in reducing Aβ plaques but has generated controversy due to differing opinions among regulatory agencies. Adverse reactions, particularly amyloid-related imaging abnormalities (ARIA), are associated with monoclonal antibody treatment. However, more extensive trials are required to establish their long-term safety and efficacy. Overall, monoclonal antibodies represent a potential breakthrough in AD treatment, although their use outside the US remains uncertain. Ongoing research and clinical trials are essential for further understanding and validating the efficacy and safety of these novel therapies.

show abstract

Section: Resultsmentioning

confidence: 99%